SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) February 23, 2000
ENZON, INC.
(Exact name of registrant as specified in its charter)
Delaware 0-12957 22-237286
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification)
20 Kingsbridge Road, Piscataway, New Jersey 08854
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (732) 980-4500
- --------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
<PAGE>
Item 5. Other Events
On February 23, 2000, Enzon, Inc. issued a press release, a copy of which
is attached as Exhibit 99.1 and incorporated by reference herein.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibit 99.1 - Press Release dated February 23, 2000.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: February 23, 2000
ENZON, INC.
----------------------
(Registrant)
By: /S/KENNETH J. ZUERBLIS
----------------------
Kenneth J. Zuerblis
Vice President, Finance
and Chief Financial
Officer
Exhibit 99.1
ENZON ANNOUNCES AWARD IN ARBITRATION WITH
YOSHITOMI FOR RECOMBINANT HSA
PISCATAWAY, NJ - February 23, 2000 -- Enzon, Inc. (NASDAQ: ENZN) announced
today that arbitrators have ruled in a royalty dispute between Enzon and
Yoshitomi Pharmaceutical Industries, Inc. Enzon was awarded a one-percent
royalty on Yoshitomi sales of recombinant Human Serum Albumin (rHSA) in Asia,
North America and South America. The product does not include any of Enzon's
platform technologies. The dispute began in 1998 regarding the royalties payable
on sales occurring in all licensed territories during the 15-year period after
the first approval in any country. In November 1997, Green Cross, the
predecessor to Yoshitomi, filed for approval to sell rHSA in Japan.
Enzon is a biopharmaceutical company developing advanced therapeutics for
life-threatening diseases through the application of its proprietary drug
delivery and targeting technologies, PEG Modification, Pro Drug/Transport
technology and Single-Chain Antigen-Binding (SCA(R)) protein technology. Enzon
has several products in various stages of clinical development by itself and
with partners, including PEG-Intron with Schering-Plough, which is in Phase III
clinical trials for malignant melanoma, chronic myelogenous leukemia and in
combination treatment with Schering-Plough's product REBETOL(R) for the
treatment of hepatitis C. Schering-Plough has filed for marketing approval in
the U.S. and Europe for PEG-INTRON for the treatment of chronic hepatitis C.
Enzon also has two products on the market, ONCASPAR, which is used to treat
Acute Lymphoblastic Leukemia (ALL), and ADAGEN a treatment for a form of Severe
Combined Immunodeficiency Disease (SCID), commonly known as the "Bubble Boy
Disease". Enzon develops and markets products on its own and through strategic
alliances, which in addition to Schering-Plough Corporation include Alexion
Pharmaceuticals, Inc., Baxter Healthcare Corporation, Bristol-Myers Squibb
Company, Eli Lilly & Company, and Rhone-Poulenc Rorer Pharmaceuticals, Inc.
Certain statements made in this press release related to potential
government approvals, market potential, commercialization and sales revenues of
medical products and biologics, as well as their therapeutic applications and
outcomes, are forward-looking and are made pursuant to the safe harbor
provisions of the Securities Litigation Reform Act of 1995. Such
<PAGE>
statements involve risks and uncertainties, which may differ materially from
those set forth in these statements. In addition, the economic, competitive,
governmental, technological and other factors identified in the Company's
filings with the Securities and Exchange Commission could affect such results.
This release is also available at http://www.enzon.com
###
